Preclinical Characterization of Selective Estrogen Receptor β Agonists: New Insights into Their Therapeutic Potential

  • H. A. Harris
Conference paper
Part of the Ernst Schering Foundation Symposium Proceedings book series (SCHERING FOUND, volume 2006/1)


It has now been over 10 years since Jan-Ake Gustafsson revealed the existence of a second form of the estrogen receptor (ERβ) at a 1996 Keystone Symposium. Since then, substantial success has been made in distinguishing its potential biological functions from the previously known form (now called ERα) and how it might be exploited as a drug target. Subtype selective agonists have been particularly useful in this regard and suggest that ERβ agonists may be useful for a variety of clinical applications without triggering classic estrogenic side effects such as uterine stimulation. These applications include inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. This manuscript will summarize illustrative data for three ERβ selective agonists, ERB-041, WAY-202196, and WAY-200070.


Selective Agonist Colonic Epithelium Estradiol Benzoate Intestinal Barrier Epithelial Function Repeat Immobilization Stress 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Our accomplishments in the field of ERβ research were enabled by the cooperative efforts of a number of scientists. First and foremost, Chris Miller, Mike Malamas, Rick Mewshaw, and Eric Manas led the chemistry effort to design and deliver highly selective ERβ agonists for biological characterization. Among the biologists, Jim Keith made key discoveries of in vivo activity; C. Richard Lyttle supported the team and suggested the endometriosis model evaluation. Several external collaborators have also contributed their expertise: Kaylon Bruner-Tran and Kevin Osteen (Vanderbilt University; endometriosis model), Kim Barrett and Silvia Resta-Lenert (University of California, San Diego; MDR1aKO mouse), Esther Sabban and Lydia Serova (New York Medical College, immobilization stress model), Steve Opal (Brown University; sepsis models). Finally I thank Rick Winneker for valuable suggestions on this manuscript.


  1. Albrecht ED, Babischkin JS, Davies WA, Leavitt MG, Pepe GJ (1999) Identification and developmental expression of the estrogen receptor alpha and beta in the baboon fetal adrenal gland. Endocrinology 140:5953–5961PubMedCrossRefGoogle Scholar
  2. Angele MK, Schwacha MG, Ayala A, Chaudry IH (2000) Effect of gender and sex hormones on immune responses following shock. Shock 14:81–90PubMedCrossRefGoogle Scholar
  3. Bowman RE, Ferguson D, Luine VN (2002) Effects of chronic restraint stress and estradiol on open field activity, spatial memory, and monoaminergic neurotransmitters in ovariectomized rats. Neuroscience 113:401–410PubMedCrossRefGoogle Scholar
  4. Bruner KL, Matrisian LM, Rodgers WH, Gorstein F, Osteen KG (1997) Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice. J Clin Invest 99:2851–2857PubMedCrossRefGoogle Scholar
  5. Buras JA, Holzmann B, Sitkovsky M (2005) Animal models of sepsis: setting the stage. Nat Rev Drug Discov 4:854–865PubMedCrossRefGoogle Scholar
  6. Crabtree JS, Zhang X, Peano BJ, Zhang Z, Winneker RC, Harris HA (2006) Development of a mouse model of mammary gland versus uterine tissue selectivity using estrogen- and progesterone-regulated gene markers. J Steroid Biochem Mol Biol 101:11–21PubMedCrossRefGoogle Scholar
  7. Cristofaro PA, Opal SM, Palardy JE, Parejo NA, Jhung J, Keith JC Jr, Harris HA (2006) WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock. Crit Care Med 34:2188–2193PubMedCrossRefGoogle Scholar
  8. Follettie MT, Pinard M, Keith JC, Wang LL, Chelsky D, Hayward C, Kearney P, Thibault P, Paramithiotis E, Dorner AJ, Harris HA (2006) Organ messenger ribonucleic acid and plasma proteome changes in the adjuvant-induced arthritis model: responses to disease induction and therapy with the estrogen receptor-beta selective agonist ERB-041. Endocrinology 147:714–723PubMedCrossRefGoogle Scholar
  9. Grummer R, Schwarzer F, Bainczyk K, Hess-Stumpp H, Regidor P, Schindler A, Winterhager E (2001) Peritoneal endometriosis: validation of an in vivo model. Human Reprod 16:1736–1743CrossRefGoogle Scholar
  10. Harris HA (2007) Estrogen receptor-beta: recent lessons from in vivo studies. Mol Endocrinol, pp 2111–2113Google Scholar
  11. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS (2002) Characterization of the biological roles of the estrogen receptors ER alpha and ER beta, in estrogen target tissues in vivo through the use of an ER alpha-selective ligand. Endocrinology 143:4172–4177PubMedCrossRefGoogle Scholar
  12. Harris HA, Albert LM, Leathurby Y, Malamas MS, Mewshaw RE, Miller CP, Kharode YP, Marzolf J, Komm BS, Winneker RC, Frail DE, Henderson RA, Zhu Y, Keith JC Jr (2003) Evaluation of an estrogen receptor-beta agonist in animal models of human disease. Endocrinology 144:4241–4249PubMedCrossRefGoogle Scholar
  13. Harris HA, Bruner-Tran KL, Zhang X, Osteen KG, Lyttle CR (2005) A selective estrogen receptor-beta agonist causes lesion regression in an experimentally induced model of endometriosis. Human Reproduction 20:936–941PubMedCrossRefGoogle Scholar
  14. Hillisch A, Peters O, Kosemund D, Muller G, Walter A, Schneider B, Reddersen G, Elger W, Fritzmeier KH (2004) Dissecting physiological roles of estrogen receptor alpha and beta with potent selective ligands from structure-based design. Mol Endocrinol 18:1599–1609PubMedCrossRefGoogle Scholar
  15. Homma H, Hoy E, Xu D-Z, Lu Q, Feinman R, Deitch EA (2005) The female intestine is more resistant than the male intestine to gut injury and inflammation when subjected to conditions associated with shock states. Am J Physiol Gastrointest Liver Physiol 288:G466–G472PubMedCrossRefGoogle Scholar
  16. Isgor C, Cecchi M, Kabbaj M, Akil H, Watson SJ (2003) Estrogen receptor beta in the paraventricular nucleus of hypothalamus regulates the neuroendocrine response to stress and is regulated by corticosterone. Neuroscience 121:837–845PubMedCrossRefGoogle Scholar
  17. Kajantie E, Phillips DIW (2006) The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology 31:151–178PubMedCrossRefGoogle Scholar
  18. Leventhal L, Brandt MR, Cummons TA, Piesla MJ, Rogers KE, Harris KA. An estrogen receptor-β agonist is active in models of inflammatory and chemical-induced pain. European Journal of Pharmacology 553:146–148Google Scholar
  19. Lund TD, Rovis T, Chung WCJ, Handa RJ (2005) Novel actions of estrogen receptor-beta on anxiety-related behaviors. Endocrinology 146:797–807PubMedCrossRefGoogle Scholar
  20. Lund TD, Hinds LR, Handa RJ (2006) The androgen 5 alpha-dihydrotestosterone and its metabolite 5 alpha-androstan-3 beta,17 beta-diol inhibit the hypothalamo-pituitary-adrenal response to stress by acting through estrogen receptor beta-expressing neurons in the hypothalamus. J Neurosci 26:1448–1456PubMedCrossRefGoogle Scholar
  21. Malamas MS, Manas ES, McDevitt RE, Gunawan I, Xu ZB, Collini MD, Miller CP, Dinh T, Henderson RA, Keith JC Jr, Harris HA (2004) Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J Med Chem 47:5021–5040PubMedCrossRefGoogle Scholar
  22. Mewshaw RE, Edsall RJ, Yang CJ, Manas ES, Xu ZB, Henderson RA, Keith JC, Harris HA (2005) ER beta ligands. 3. Exploiting two binding orientations of the 2-phenylnaphthalene scaffold to achieve ER beta selectivity. J Med Chem 48:3953–3979PubMedCrossRefGoogle Scholar
  23. Miller CP (2002) SERMs: evolutionary chemistry, revolutionary biology. Curr Pharmaceut Des 8:2089–2111CrossRefGoogle Scholar
  24. Miller WJS, Suzuki S, Miller LK, Handa R, Uht RM (2004) Estrogen receptor (ER)beta isoforms rather than ER alpha regulate corticotropin-releasing hormone promoter activity through an alternate pathway. J Neurosci 24:10628–10635PubMedCrossRefGoogle Scholar
  25. Resta-Lenert S, Smitham J, Barrett KE (2005) Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a(-/-) mice. Am J Physiol Gastrointest Liver Physiol 289:G153–G162PubMedCrossRefGoogle Scholar
  26. Saunders PTK, Maguire SM, Gaughan J, Millar MR (1997) Expression of oestrogen receptor beta (ER-beta) in multiple rat tissues visualised by immunohistochemistry. J Endocrinol 154:R13–R16PubMedCrossRefGoogle Scholar
  27. Serova LI, Maharjan S, Sabban EL (2005) Estrogen modifies stress response of catecholamine biosynthetic enzyme genes and cardiovascular system in ovariectomized female rats. Neuroscience 132:249–259PubMedCrossRefGoogle Scholar
  28. Shughrue PJ, Lane MV, Merchenthaler I (1997) Comparative distribution of estrogen receptor-alpha and -beta mRNA in the rat central nervous system. J Comp Neurol 388:507–525PubMedCrossRefGoogle Scholar
  29. Tonelli L, Kramer P, Webster JI, Wray S, Listwak S, Sternberg E (2002) Lipopolysaccharide-induced oestrogen receptor regulation in the paraventricular hypothalamic nucleus of Lewis and Fischer rats. J Neuroendocrinol 14:847–852PubMedCrossRefGoogle Scholar
  30. Veeneman GH (2005) Non-steroidal subtype selective estrogens. Curr Med Chem 12:1077–1136PubMedCrossRefGoogle Scholar
  31. Vincent J-L, Abraham E (2005) The last 100 years of sepsis. Am J Respir Crit Care Med 173:256–263PubMedCrossRefGoogle Scholar
  32. Walf AA, Frye CA (2005) Antianxiety and antidepressive behavior produced by physiological estradiol regimen may be modulated by hypothalamic-pituitary-adrenal axis activity. Neuropsychopharmacology 30:1288–1301PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Wyeth ResearchWomen's Health Research InstituteCollegeville PAUSA

Personalised recommendations